Preclinical evaluation of dual inhibitors activates antitumor immunity against triple-negative breast cancer, indicating potential therapeutic benefits.
represents a valuable preclinical candidate for further development as an immunomodulatory antitumor agent.
No takes yet. Share an insight, caveat, or question.
CHEN et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: